Tarsus Pharmaceuticals, Inc. TARS
75.69
(0.27)
(0.36%)
as of 25 Sep
- Market cap
- $3.6B
- P/E
- 0.0×
Follow TARS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(28.35%) | (23.39%) | (13.96%) | (13.68%) | |
| (17.82%) | (14.14%) | (8.92%) | (8.40%) | ||
ROIC |
(988.67%) | 0.00% | (96.77%) | 0.00% | |
Return on Tangible Assets |
(20.79%) | (16.66%) | (11.73%) | (11.43%) | |
Average Days of Receivables |
74.11 | 70.44 | 79.95 | 59.18 | |
Free Cash Flow per Share |
(1.35) | (0.53) | (0.73) | 1.29 | |
Free Cash Flow |
(57.54) | (22.31) | (31.54) | 56.00 | |
Capital Expenditures |
(3.57) | (9.86) | (15.09) | (18.15) | |
Piotroski F-Score |
5.00 | 5.00 | 5.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
(6.67%) | (1.49%) | (2.03%) | 8.53% | |
Accounts Receivable Turnover |
7.00 | 6.68 | 5.90 | 7.65 | |
Accounts Payable Turnover |
0.31 | 2.38 | 0.69 | 0.69 | |
Inventory Turnover |
7.39 | 8.78 | 9.58 | 9.88 | |
Average Days of Payables |
1,530.48 | 194.93 | 252.60 | 359.59 | |
Days of Inventory on Hand |
56.72 | 52.01 | 47.86 | 39.21 | |
Tax Rate |
0.00 | 0.00 | 0.05 | 0.13 | |
Research and Development Expense of Revenue |
17.25% | 14.25% | 13.51% | 14.46% | |
Selling, General and Administrative Expense of Revenue |
99.88% | 94.67% | 89.47% | 86.82% | |
Share Based Compensation of Revenue |
9.51% | 9.24% | 8.74% | 8.55% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.66 | 0.19 | 0.34 | (1.60) | |
Depreciation/Fixed assets |
(0.64) | (0.26) | (0.15) | (0.05) | |
Capex/Depreciation |
0.98 | 3.21 | 5.78 | 16.55 | |
Revenue per Share |
8.59 | 10.80 | 12.46 | 13.97 | |
Operating CF per Share |
(1.27) | (0.30) | (0.38) | 1.71 | |
Capex per Share |
(0.08) | (0.24) | (0.35) | (0.42) | |
Capex to Sales |
0.01 | 0.02 | 0.03 | 0.03 | |
Net Profit Margin |
(22.17%) | (14.72%) | (9.02%) | (7.67%) |
Columns are period end dates